PRODUCTnews

Clobetasol Propionate Foam

Marketed by:

Perrigo Co (Allegan, MI)

Compared to:

Olux Foam (Connectics Corp.

Indication:

March 20, 2008?Perrigo Co announced the launch of Clobetasol Propionate Foam. The US District Court for the District of New Jersey denied Connetics Corporation?s motion for a preliminary injunction related to Perrigo?s Clobetasol Propionate Foam and lifted the temporary restraints that prevented Perrigo?s launch. As the first company to file, Perrigo receives 180-day generic exclusivity. Clobetasol Propionate Foam is a topical corticosteroid indicated for the treatmentof moderate-to-severe dermatitis of the scalp.

Dosage Form:

0.05% Foam in 50- and 100-mg cans

For More Information:

www.perrigo.com

Griseofulvin Oral Suspension USP

Marketed by:

Teva Pharmaceuticals (North Wales, PA)

Compared to:

Grifulvin V (Johnson & Johnson Corp)

Indication:

February 12, 2008?Teva Pharmaceuticals announced the introduction and availability of Griseofulvin Oral Suspension USP. Major indications for griseofulvin include: tinea capitis (ringworm of the scalp), tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea unguium (ringworm of the nails), tinea cruris (ringworm of the thigh), and tinea barbae (barber?s itch). Griseofulvin acts systemically to inhibit the growth of the Trichophyton, Microsporum, and Epidermophyton genera of fungi.

Dosage Form:

Oral suspension: 125 mg/5 mL in a 120-mL bottle

For More Information:

www.tevausa.com

Neomycin and Polymyxin B Sulfates and Gramicidin Ophthalmic Solution, USP

Marketed by:

Paddock Laboratories (Minneapolis, MN)

Compared to:

Neomycin and Polymyxin B Sulfates and Gramicidin Ophthalmic Solution, USP (Bausch and Lomb)

Indication:

January 2, 2008?Paddock Laboratories announced the availability of Neomycin and Polymyxin B Sulfates and Gramicidin Ophthalmic Solution, USP. The solution is indicated for the topicaltreatment of superficial infections of the external eye and its adnexa, such as conjunctivitis, keratitis,blepharitis, etc, caused by susceptible bacteria.

Dosage Form:

1.75 mg (base)/mL, 10,000 units/mL, 0.025 mg/mL;10-mL bottle

For More Information:

www.paddocklabs.com

Oxycodone HCl 10- and 20-mg Tablets

Marketed by:

ETHEX Corp (St. Louis, MO)

Indication:

April 3, 2008?ETHEX Corp announced the introduction of 2 new strengths of immediate-release Oxycodone HCl Tablets?10 and 20 mg. The new 10- and 20-mg strengths are designed tobridge the gap between existing oxycodone HCl strengths, providing prescribers and patients with greater dosing flexibility. ETHEX is the only company to offer immediate-release oxycodone HCl tablets in 5 strengths: 5, 10, 15, 20, and 30 mg. These tablets are indicated for the relief of moderate-to-severe pain where the use of an opioid analgesic is appropriate.

Dosage Form:

Tablets: 5, 10, 15, 20, and 30 mg

For More Information:

www.ethex.com